ArticleFrontiers in microbiology2026
BCS2.0: a capture sequencing platform for rapid differential diagnosis of bacterial infections and antimicrobial resistance.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The "Golden Hour" is the period immediately after trauma, stroke or a cardiac event when rapid intervention is critical to reducing morbidity and mortality. The same principle should also apply to infectious diseases. Rapid, sensitive detection of infectious agents, enabling targeted interventions, has the potential to reduce mortality, morbidity, and costs of infectious diseases, and to decrease the inappropriate use of antibiotics that drives the evolution of antimicrobial resistance (AMR). Methods: Probes were designed to represent the MetaPhlAn4 database covering 894 known or potential pathogenic bacterial species, 16S rRNA sequences from the SILVA database comprising 1,325 potentially pathogenic bacterial species, genes in the Virulence Factor Database and antimicrobial resistance determinants in the Comprehensive Antibiotic Resistance Database. Target sequences were tiled with 120 nucleotide probes distributed at 60 nt intervals and clustered at 99% sequence identity. Performance measures included limits of detection (LOD) and assay reproducibility in plasma and urine using contrived and clinical samples. Results: Analytical validation using 20 bacterial strains in contrived plasma and urine samples confirmed an LOD of 5 colony-forming units per milliliter and detection of mixed infections. Results obtained with urine and blood cultures were concordant with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI), and Blood Culture Identification (BCID) assays. Discussion: BCS2.0 enables sensitive detection of bacterial species and AMR genes and has the potential to expedite rapid, efficient infectious disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.